FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) has beefed up its board with the appointment of Dr Larry Kaiser, who brings with him "decades of academic and senior executive experience in medicine and the delivery of healthcare in the United States".
He becomes a director of the company with immediate effect.
READ: FSD Pharma starts trading on Nasdaq
"Dr. Kaiser brings substantial depth and strength to our board of directors," Raza Bokhari, the executive co-chairman and CEO of FSD Pharma, told investors Wednesday.
"Dr. Kaiser has already contributed immensely as chairman of our world-class scientific advisory board, where his input has been very meaningful in shaping our Biosciences strategy to focus on assembling synthetic compounds that target the CB2 receptors of the endocannabinoid system of the human body.
"As a director, we are relying on his leadership and sage counsel as we continue to double down on our Biosciences effort to eventually bring to market prescription-based drugs by conducting rigorous FDA-approved clinical trials."
Dr Kaiser is author or co-author of 17 books and more than 300 original papers, and he serves on multiple editorial boards, including the 'Annals of Surgery', the world’s leading surgical journal.
He is currently the managing director with the Healthcare Industry Group at Alvarez and Marsal, a leading global professional services firm.
Most recently, he was the president and CEO of the US$2.2 billion Temple University Health System (Temple), Dean of Temple University’s Lewis Katz School of Medicine, and senior executive vice president for Health Sciences at Temple University.
He graduated AOA (Alpha Omega Alpha Honor Medical Fraternity) from the Tulane University School of Medicine in 1977 and completed his residency in general surgery, as well as a fellowship in surgical oncology at the University of California, Los Angeles.
Residency in cardiovascular and thoracic surgery
He then completed a residency in cardiovascular and thoracic surgery at the University of Toronto.
FSD Pharma is working on a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system.
Shares slipped 8% in Toronto to C$9.01.
Contact the author at [email protected]
